The brightening future of HIV therapeutics
- 1 September 2004
- journal article
- review article
- Published by Springer Nature in Nature Immunology
- Vol. 5 (9) , 867-871
- https://doi.org/10.1038/ni0904-867
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Structure and Function of HIV-1 IntegraseCurrent Topics in Medicinal Chemistry, 2004
- Antiviral drugs in current clinical usePublished by Elsevier ,2004
- Can the Use of HIV-1 Derived Gene Transfer Vectors for Clinical Application be Justified?Current Gene Therapy, 2004
- Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542Antimicrobial Agents and Chemotherapy, 2004
- Antiretroviral Activity of the Anti‐CD4 Monoclonal Antibody TNX‐355 in Patients Infected with HIV Type 1The Journal of Infectious Diseases, 2004
- The entry of entry inhibitors: A fusion of science and medicineProceedings of the National Academy of Sciences, 2003
- Single‐Dose Safety, Pharmacology, and Antiviral Activity of the Human Immunodeficiency Virus (HIV) Type 1 Entry Inhibitor PRO 542 in HIV‐Infected AdultsThe Journal of Infectious Diseases, 2000
- CHEMOKINE RECEPTORS AS HIV-1 CORECEPTORS: Roles in Viral Entry, Tropism, and DiseaseAnnual Review of Immunology, 1999
- Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibodyNature, 1998
- Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural GeneScience, 1996